A. D'Alonzo

Erratum to: Analysis of in vitro ADCC and clinical response to trastuzumab: Possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines [J Transl Med (2015) 13:324] DOI: 10.1186/s12967-015-0680-0

© 2016 Boero et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/ publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Erratum to: J Transl Med (2015) 13:324 DOI 10.1186/s12967‐015‐0680‐0 It has come the publisher’s attention that the original version of this article [1] unfortunately contained an error. In Table 3, first column, the FcγRIIA 131 H>R genotypes were incorrectly labelled. In particular, V/V should have read H/H, V/F should have read H/R and F/F should have read R/R. Please note that this correction does not change the genotype numerical values of FcγRIIA polymorphism. The correct Table 3 has been published as Table 1 in this Erratum. Open Access Journal of Translational Medicine

PO54 ACTIVITY AND DURATION OF CHEMOTHERAPY IN DIFFERENT BIOLOGIC SUBTYPES (BS) IN METASTATIC BREAST CANCER (MBC) PATIENTS

Background: In MBC patients the benefit of chemotherapy after the first line is poorly defined. We evaluated activity of subsequent line of chemotherapy in different BS of MBC. Methods: MBC patients treated in our center from 2007 to 2012 with ER, PgR and HER2 on primary tumor and at least one line of chemotherapy for MBC were evaluated. Patients were classified as luminal A (ER and/ or PgR +, HER2 -, Ki67 ≤ 14%), luminal B (ER and/or PgR +, HER2 -, Ki67 > 14%), HER2+ (HER2+, any ER/PgR) and triple-negative (ER-, PgRand HER2-). The objectives of our analysis were to estimate number of chemotherapy lines in different BS, to evaluate clinical benefit (CB) defined as RC+RP+SD and overall survival (OS) by chemotherapy line in every BS and to identify possible predictive factors for a greater number of chemotherapy line. Time on chemotherapy was calculated from the start of the first line to the end of the last line. Statistical analyses included Chi-square and Kruskal-Wallis tests, Kaplan-Meier curves and log-rank tests, and multivariate logistic regressions. Results: A total of 326 patients were identified, 50 were excluded because they did not receive any chemotherapy. Median follow-up was 32.3 months. Median number of chemotherapy lines was 2 (range 1-10). Median OS according to BS was 60.5 months in luminal A (58 patients), 50.0 months in luminal B (119 patients), 69.2 in HER2+ (57 patients) and 32.3 in TN (42 patients). The percentages of patients receiving second line, third line and four or more lines of chemotherapy were respectively: 58%, 41%, 22% for luminal A, 59%, 34%, 16% for luminal B, 71%, 52%, 39% for HER2+, and 69%, 43%, 16% for TN. CB was inferior in TN patients as compared with the other ones in first and in second lines (p=.027 and p=.093 respectively in first and second lines). From third line onward all patients showed the same CB independently from BS. Time on chemotherapy related to median OS for every BS was the same (18% in luminal A, 20% in luminal B, 27% in HER2+, 29% in TN). At multivariate analysis the characteristics independently associated with a greater probability of receiving more than four chemotherapy lines were HER2+ (p=.027) and less than three sites of metastasis (p=.05). Conclusions: Our analysis showed that, despite the same time spent on chemotherapy, TN patients received less benefit from first and second chemotherapy lines than other BS. On the other hand, HER2+ patients were more likely to receive multiple lines of chemotherapy with a significant impact on median OS (p=.044). PO55

HM35 Role of temporary ovarian suppression obtained with GnRH analogue in reducing premature ovarian failure induced by chemotherapy in premenopausal cancer patients: a meta-analysis of randomized studies

OR34 Sexual functioning in young women with breast cancer S. Rosenberg *, R. Tamimi, S. Gelber, K. Ruddy, S. Kereakoglow, V. Borges, S. Come, L. Schapira, E. Winer, A. Partridge. Harvard School of Public Health, Department of Epidemiology, Boston, USA, Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA, University of Colorado-Denver, Department of Medical Oncology, Denver, USA, Beth Israel Deaconess Medical Center, Department of Medical Oncology, Boston, USA, Massachusetts General Hospital, Department of Medical Oncology, Boston, USA